# Piramal Pharma (NSE: PPLPHARMA) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/PPLPHARMA · Pivot · prices to 21 Oct 2026

Piramal Pharma (NSE: PPLPHARMA) closed at ₹192.55 on 21 Oct 2026, up 2.19% on the day. With a market capitalisation of ₹26,393 Cr, it ranks 302nd by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

At its last close the stock traded at 25× trailing earnings, against a return on equity of −4.0% in FY26. Over the past year the share price has risen 0.4%. Its 52-week range is ₹132.30 (23 Mar 2026) to ₹231.93 (8 Sep 2026); the last close is 17.0% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹2,270 Cr (+17.4% year on year) and net profit −₹89 Cr, on a consolidated basis. Promoters held 34.80% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹192.55 |
| Market cap | ₹26,393 Cr |
| P/E (trailing) | 25 |
| ROE | −4.0% (FY26) |
| ROCE | 2.3% (FY26) |
| Debt to equity | 0.67 |
| 52-week high | ₹231.93 (8 Sep 2026) |
| 52-week low | ₹132.30 (23 Mar 2026) |
| 1-year return | +0.4% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q1 FY27 | ₹2,270 Cr | +17.4% | −₹89 Cr | — | −₹0.52 |
| Q4 FY26 | ₹2,752 Cr | −0.1% | −₹22 Cr | −116.3% | −₹0.07 |
| Q3 FY26 | ₹2,140 Cr | −2.9% | −₹146 Cr | — | −₹1.03 |
| Q2 FY26 | ₹2,044 Cr | −8.8% | −₹114 Cr | −2,239.0% | −₹0.75 |
| Q1 FY26 | ₹1,934 Cr | −0.9% | −₹100 Cr | — | −₹0.62 |
| Q4 FY25 | ₹2,754 Cr | +7.9% | ₹137 Cr | +53.8% | ₹1.16 |
| Q3 FY25 | ₹2,204 Cr | +12.5% | −₹13 Cr | — | ₹0.03 |
| Q2 FY25 | ₹2,242 Cr | +17.3% | ₹5 Cr | — | ₹0.17 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY26 | ₹8,869 Cr | −₹383 Cr |
| FY25 | ₹9,151 Cr | ₹18 Cr |
| FY24 | ₹8,171 Cr | −₹42 Cr |
| FY23 | ₹7,082 Cr | −₹241 Cr |
| FY22 | ₹6,559 Cr | ₹317 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 34.80%
- Foreign institutions: 12.52%
- Domestic institutions: 14.57%
- Non-institutions: 37.63%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Wockhardt](https://app.pivotnow.in/stock/WOCKPHARMA) | ₹1,905.90 | ₹30,969 Cr | 146 | 4.3% |
| [Sai Life Sciences](https://app.pivotnow.in/stock/SAILIFE) | ₹1,377.60 | ₹29,245 Cr | 83.9 | 8.0% |
| [Krishna Institute of Medical Sciences](https://app.pivotnow.in/stock/KIMS) | ₹672.75 | ₹28,256 Cr | 112.1 | 18.0% |
| [Neuland Laboratories](https://app.pivotnow.in/stock/NEULANDLAB) | ₹18,745.00 | ₹24,050 Cr | 65.9 | 19.4% |
| [Rubicon Research](https://app.pivotnow.in/stock/RUBICON) | ₹1,433.20 | ₹23,703 Cr | 93.9 | 19.1% |
| [Procter Gamble](https://app.pivotnow.in/stock/PGHH) | ₹7,006.50 | ₹22,744 Cr | 26.5 | 62.3% |

## Questions and answers

### What is the share price of Piramal Pharma today?

Piramal Pharma (NSE: PPLPHARMA) last closed at ₹192.55 on 21 Oct 2026. Its 52-week high is ₹231.93 and its 52-week low is ₹132.30.

### What is the market cap of Piramal Pharma?

Piramal Pharma's market capitalisation is ₹26,393 Cr (₹26,393 Cr) at the 21 Oct 2026 close, ranking 302nd among the NSE companies Pivot tracks.

### What is the P/E ratio of Piramal Pharma?

Piramal Pharma trades at a trailing P/E of 25. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 93.9.

### What is the ROE and ROCE of Piramal Pharma?

Return on equity was −4.0% in FY26 and return on capital employed was 2.3% in FY26 (consolidated figures).

### Is Piramal Pharma a debt-free company?

No. Piramal Pharma's debt-to-equity ratio was 0.67 in FY26, with total debt of ₹4,300 Cr.

### What were Piramal Pharma's latest quarterly results?

For Q1 FY27 (quarter ended 30 Jun 2026), Piramal Pharma reported revenue of ₹2,270 Cr, +17.4% year on year, and net profit of −₹89 Cr.

### How has Piramal Pharma stock performed over the last year?

Piramal Pharma's share price has risen 0.4% over the past year, +7.0% over three months and −5.2% over one month, to the 21 Oct 2026 close.

### What is the shareholding pattern of Piramal Pharma?

As of 30 Jun 2026: promoters 34.80%, foreign institutions 12.52%, domestic institutions 14.57%, non-institutions 37.63%.

### Who are Piramal Pharma's competitors?

The listed Pharma & Healthcare companies closest to Piramal Pharma by market cap are Wockhardt, Sai Life Sciences, Krishna Institute of Medical Sciences, Neuland Laboratories, Rubicon Research and Procter Gamble.

### Is Piramal Pharma a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Piramal Pharma's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on PPLPHARMA against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.